Bexmarilimab: Audience

Bexmarilimab is a first-in-class anti-Clever-1 antibody developed by Faron Pharmaceuticals, aimed at treating hematological cancers and solid tumors. It leverages the patient's immune system to enhance the efficacy of existing cancer treatments.